References
1. Schnabel RB, Yin X, Gona P, Larson MG, Beiser A, Mcmanus DD,
Newtoncheh C, Lubitz SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA,
Vasan RS, Benjamin EJ, Levy D: 50 year trends in atrial fibrillation
prevalence, incidence, risk factors, and mortality in the Framingham
Heart Study: a cohort study. Lancet 2015;386:154-162.
2. Zoniberisso M, Lercari F, Carazza T, Domenicucci S: Epidemiology of
Atrial Fibrillation: European Perspective. Clin Epidemio 2014;6:213-220.
3. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA: Atrial
fibrillation and risks of cardiovascular disease, renal disease, and
death: systematic review and meta-analysis. Clin Epidemio 2016;354:i4482
4. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin
EJ, Gillum RF, Kim YH, Mcanulty JH, Zheng ZJ, Forouzanfar MH, Naghavi M,
Mensah GA, Ezzati M, Murray CJ: Worldwide Epidemiology of Atrial
Fibrillation A Global Burden of Disease 2010 Study. Circulation
2014;129:837-847.
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer
DE: Prevalence of Diagnosed Atrial Fibrillation in Adults: National
Implications for Rhythm Management and Stroke Prevention: the
AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study.
JAMA 2001;285:2370-2375.
6. Heeringa J, van der Kuip DA,
Hofman A, Kors JA, van Herpen G,
Stricker BHC, Stijnen T, Lip GY, Witteman JC: Prevalence, incidence and
lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J
2006;27:949-953.
7. Thongprayoon C, Chokesuwattanaskul R, Bathini T, Khoury NJ, Sharma K,
Ungprasert P, Prasitlumkum N, Aeddula NR, Watthanasuntorn K, Salim SA,
Kaewput W, Koller FL, Cheungpasitporn W: Epidemiology and Prognostic
Importance of Atrial Fibrillation in Kidney Transplant Recipients: A
Meta-Analysis. J Clin Med 2018;7:370.
8. Chokesuwattanaskul R, Thongprayoon C, Bathini T, Ungprasert P, Sharma
K, Wijarnpreecha K, Pachariyanon P, Cheungpasitporn W: Liver
transplantation and atrial fibrillation: A meta-analysis. World Journal
of Hepatology 2018;10:761-771.
9. Brennan DC: Long-term trends in allograft survival. Adv Chronic
Kidney D 2006;13:11-17.
10. Sanchez CA, Higueras MM, Fernandez-Felechosa JM, Gutierrez JM,
Moreno PM, Fernandez NG, Royo FL, Goenaga PE: Short-term outcomes of 100
consecutive kidney transplantations in a 3-year period: a single-center
experience. Transpl P 2016;48:2906-2909.
11. Molinari M, Sood P, Samra PB, Tevar AD, Ganoza A, Jonassaint N,
Puttarajappa C: Atrial fibrillation in renal or liver transplant
recipients: A systematic review and meta-analysis. Transplantation
Reviews 2019;33:29-38.
12. Bargehr J, Trejogutierrez JF, Patel TC, Rosser BG, Arandamichel J,
Yataco M, Taner CB: Preexisting atrial fibrillation and cardiac
complications after liver transplantation. Liver Transplant
2015;21:314-320.
13. Lenihan CR, Montezrath ME, Scandling JD, Turakhia MP, Winkelmayer
WC: Outcomes After Kidney Transplantation of Patients Previously
Diagnosed With Atrial Fibrillation. Am J Transplant 2013;13:1566-1575.
14. Marincasino M, Perezsaez MJ, Crespo M, Echeverria D, Mir M, Pascual
J: Significant tacrolimus and dronedarone interaction in a kidney
transplant recipient. Transplantation 2014;98:33-34
15. Tichy EM, Medwid AJ, Mills EA, Formica RN, Kulkarni S: Significant
Sirolimus and Dronedarone Interaction in a Kidney Transplant Recipient.
Ann Pharmacother 2010;44:1338-1341.
16. Burger CI, Clase CM, Gangji AS: Case report: drug interaction
between tacrolimus and amiodarone with QT prolongation. Transplantation
2010;89:1166-1167.
17. Kisters K, Cziborra M, Funke C, Brylak S, Hausberg M:
Amiodarone-tacrolimus interaction in kidney transplantation. Clin
Nephrol 2008;70:563.
18. Leon J, Sabbah L, Aubert O, Anglicheau D, Delavenne X, Zuber J,
Amrouche L, Scemla A, Giura G, Divard G, Legendre C, Sberro-Soussan R:
Efficacy and safety of direct oral anticoagulants in kidney
transplantation: a single-center pilot experience. Transplantation 2020.
19. Salerno DM, Tsapepas D, Papachristos A, Chang J, Martin ST, Hardy
MA, Mckeen J: Direct oral anticoagulant considerations in solid organ
transplantation: A review. Clin Transplant 2017;31: 10.1111/ctr.12873
20. Calkins H, Hindricks G, Cappato R, et al: 2017
HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and
surgical ablation of atrial fibrillation. Heart Rhythm 2017;14:275-444.
21. Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX, Ning M, Liu N,
Liu XP, Du X, Tse HF, Ma CS: Prospective randomized comparison between a
fixed ‘2C3L’ approach vs. stepwise approach for catheter ablation of
persistent atrial fibrillation. Europace 2015;17:1798-1806.
22. De Mattos AM, Prather JC, Olyaei AJ, Shibagaki Y, Keith D, Mori M,
Norman DJ, Becker T: Cardiovascular events following renal
transplantation: Role of traditional and transplant-specific risk
factors. Kidney Int 2006;70:757-764.
23. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J:
Cardiovascular morbidity and mortality after orthotopic liver
transplantation. Transplantation 2002;73:901-906.
24. Fussner LA, Heimbach JK, Fan C, Dierkhising RA, Coss E, Leise MD,
Watt KD: Cardiovascular disease after liver transplantation: When, What,
and Who Is at Risk. Liver Transplant 2015;21:889-896.
25. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ: Immunosuppression impact
on long-term cardiovascular complications after liver transplantation.
Am J Surg 2002;183:595-599.
26. Gill JS: Cardiovascular Disease in Transplant Recipients: Current
and Future Treatment Strategies. Clin J Am Soc Nephrol 2008;3:S29-37
27. Mark DB, Anstrom KJ, Sheng S, Piccini JP, Baloch K, Monahan KH,
Daniels MR, Bahnson TD, Poole JE, Rosenberg Y, Lee KL, Packer DL; CABANA
Investigators: Effect of Catheter Ablation vs Medical Therapy on Quality
of Life Among Patients With Atrial Fibrillation: The CABANA Randomized
Clinical Trial. JAMA 2019;321:1275-1285.
28. Blomstromlundqvist C, Gizurarson S, Schwieler J, Jensen SM,
Bergfeldt L, Kenneback G, Rubulis A, Malmborg H, Raatikainen P,
Lonnerholm S, Hoglund N, Mortsell D: Effect of Catheter Ablation vs
Antiarrhythmic Medication on Quality of Life in Patients With Atrial
Fibrillation: The CAPTAF Randomized Clinical Trial. JAMA
2019;321:1059-1068.
29. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma LVA,
Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H,
Christ H, Vogt J, Bansch D; CASTLE-AF Investigators: Catheter Ablation
for Atrial Fibrillation with Heart Failure. New Engl J Med
2018;378:417-427.
30. Lin H, Wolf PA, Kellyhayes M, Beiser A, Kase CS, Benjamin EJ,
D’Agostino RB: Stroke Severity in Atrial Fibrillation The Framingham
Study. Stroke 1996;27:1760-1764.
31. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L,
Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N,
Sinnaeve P, Collins R, Camm AJ, Heidbuchel H; ESC Scientific Document
Group: The 2018 European Heart Rhythm Association Practical Guide on the
use of non-Vitamin K antagonist oral anticoagulants in patients with
atrial fibrillation. Eur Heart J 2018;39:1330-1393.
32. Lenihan CR, Montezrath ME, Shen JI, Scandling JD, Turakhia MP, Chang
TI, Winkelmayer WC: Correlates and outcomes of warfarin initiation in
kidney transplant recipients newly diagnosed with atrial fibrillation.
Nephrol Dial Transpl 2015;30:321-329.
33. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N,
Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T,
Antman EM: Comparison of the efficacy and safety of new oral
anticoagulants with warfarin in patients with atrial fibrillation: a
meta-analysis of randomised trials. Lancet 2014;383:955-962.
34. Vanhove T, Spriet I, Annaert P, Maertens J, Van Cleemput J, Vos R,
Kuypers D: Effect of the Direct Oral Anticoagulants Rivaroxaban and
Apixaban on the Disposition of Calcineurin Inhibitors in Transplant
Recipients. Ther Drug Monit 2017;39:77-82.
35. Wannhoff A, Weiss KH, Schemmer P, Stremmel W, Gotthardt D: Increased
levels of rivaroxaban in patients after liver transplantation treated
with cyclosporine A. Transplantation 2014;98:12-13